| P/E (FY) | — | Sales (TTM) | €2.7M |
| Earnings (TTM) | -€12.9M | ROE | — |
| Net Margin | −470.86% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
BioSenic S.A. is a biotechnology company developing cell therapy products and treatments for autoimmune and inflammatory diseases, with operations in Belgium and France. Its work centers on arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms, including ArsciMed, an intravenous drug for autoimmune conditions, and 4P004v, a Phase I candidate for veterinary use. The company is headquartered in Saintes, Belgium.
| Market Cap | — | Trading Days | 2888 |
| 52W High | 0.00 |
| 52W Low | 0.00 |
| % Off High | −28.57% |
| YTD | −13.04% | 1Y | −20.00% |
| 3Y | −96.31% | 5Y | −99.92% |
| 10Y | −99.99% | Since incept. (ann.) | −54.30% |
| Ann. Volatility (1Y) | 65.56% | Ann. Volatility (3Y) | 148.69% |
| Sharpe (1Y) | −0.02 | Sharpe (3Y) | −0.13 |
| Max Drawdown (1Y) | −28.57% | Max Drawdown (3Y) | −99.13% |
| Beta (3Y, vs SPY) | −1.14 |
No same-industry peers in the universe for BIOS.BR.
